Hypothalamic transcriptomics revealed dysregulation of endocrine signaling pathways, with functional analyses confirming defects in insulin, leptin, and cholecystokinin (CCK) signaling, while glucagon-like peptide-1 receptor (GLP-1R) responsiveness was preserved
These medications stimulate insulin secretion from the pancreas while inhibiting the release of glucagon, leading to lower blood sugar levels
Glucagon Receptor A receptor that, when activated alongside GLP-1 activity, promotes thermogenesis and fat oxidation rather than producing its typical hyperglycemic effect in isolation
The right response is curiosity with a firm grip on what the evidence does and does not show
One theory, according to a CBS report, is that the medication decreases appetite, which may lead people to eat less and therefore get fewer calories for their body to use as fuel